Evolution of proviral DNA HIV-1 tropism under selective pressure of maraviroc-based therapy

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 6, 2012, Pages 1479-1485

  Baroncelli, Silvia ^a   Galluzzo, Clementina Maria ^a   Weimer, Liliana Elena ^a   Pirillo, Maria Franca ^a   Volpe, Anna ^b   Mercuri, Alessandra ^c   Cavalli, Albertina ^d   Fragola, Vincenzo ^b   Monno, Laura ^b   Degli Antoni, Anna ^d   Ladisa, Nicoletta ^b   Francisci, Daniela ^c   Bucciardini, Raffaella ^a   Floridia, Marco ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b UNIVERSITY OF BARI   (Italy)

^c UNIVERSITY OF PERUGIA   (Italy)

^d UNIVERSITY HOSPITAL OF PARMA   (Italy)

Author keywords

CCR5 inhibitors; Highly active antiretroviral therapy; HIV 1 coreceptor; V3 genotype

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; ENFUVIRTIDE; LAMIVUDINE; MARAVIROC; RALTEGRAVIR; VIRUS DNA; VIRUS RNA;

ADULT; ARTICLE; BLOOD SAMPLING; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL PRACTICE; CORRELATION ANALYSIS; FEMALE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MALE; MULTICENTER STUDY; NONHUMAN; OBSERVATIONAL STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PREDICTION; PREVALENCE; PROVIRUS; VIRAL TROPISM;

ADULT; ANTI-HIV AGENTS; CYCLOHEXANES; DNA, VIRAL; EVOLUTION, MOLECULAR; FEMALE; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PROVIRUSES; SELECTION, GENETIC; TRIAZOLES; VIRAL TROPISM;

EID: 84861108454     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks055     Document Type: Article

References (41)

1. Deng H, Liu R, Ellmeier W et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996; 381: 661-6.
2. Westby M, Lewis M, Whitcomb J et al. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J Virol 2006; 80: 4909-20.
3. Westby M, Smith-Burchnell C, Mori J et al. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J Virol 2007; 81: 2359-71.
4. Tilton JC, Wilen CB, Didigu CA et al. A maraviroc-resistant HIV-1 with narrow cross-resistance to other CCR5 antagonists depends on both N-terminal and extracellular loop domains of drug-bound CCR5. J Virol 2010; 84: 10863-76.
5. Cooper DA, Heera J, Goodrich J et al. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. J Infect Dis 2010; 201: 803-13.
6. Fätkenheuer G, Nelson M, Lazzarin A et al. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med 2008; 359: 1442-55.
7. Koot M, Keet IP, Vos AH et al. Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med 1993; 118: 681-8.
8. Maas JJ, Gange SJ, Schuitemaker H et al. Strong association between failure of T cell homeostasis and the syncytium-inducing phenotype among HIV-1-infected men in the Amsterdam Cohort Study. AIDS 2000; 14: 1155-61.
9. Weiser B, Philpott S, Klimkait T et al. HIV-1 coreceptor usage and CXCR4-specific viral load predict clinical disease progression during combination antiretroviral therapy. AIDS 2008; 22: 469-79.
10. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. U.S. Department of Health and Human Services. January 10, 2011; 1-166. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf (1 October 2011, date last accessed).
11. Seclén E, Garrido C, González Mdel M et al. High sensitivity of specific genotypic tools for detection of X4 variants in antiretroviral-experienced patients suitable to be treated with CCR5 antagonists. J Antimicrob Chemother 2010; 65: 1486-92.
12. Vandekerckhove LP, Wensing AM, Kaiser R et al. European guidelines on the clinical management of HIV-1 tropism testing. Lancet Infect Dis 2011; 11: 394-407.
13. Shioda T, Levy JA, Cheng-Mayer C. Macrophage and T cell-line tropisms of HIV-1 are determined by specific regions of the envelope gp120 gene. Nature 1991; 349: 167-9.
14. Hoffman NG, Seillier-Moiseiwitsch F, Ahn J et al. Variability in the human immunodeficiency virus type 1 gp120 Env protein linked to phenotype-associated changes in the V3 loop. J Virol 2002; 76: 3852-64.
15. Delobel P, Sandres-Sauné K, Cazabat M et al. R5 to X4 switch of the predominant HIV-1 population in cellular reservoirs during effective highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2005; 38: 382-92.
16. Saracino A, Monno L, Punzi G et al. HIV-1 biological phenotype and predicted coreceptor usage based on V3 loop sequence in paired PBMC and plasma samples. Virus Res 2007; 130: 34-42.
17. Frange P, Galimand J, Goujard C et al. High frequency of X4/DM-tropic viruses in PBMC samples from patients with primary HIV-1 subtype-B infection in 1996-2007: the French ANRS CO06 PRIMO Cohort Study. J Antimicrob Chemother 2009; 64: 135-41.
18. Verhofstede C, Vandekerckhove L, Eygen VV et al. CXCR4-using HIV type 1 variants are more commonly found in peripheral blood mononuclear cell DNA than in plasma RNA. J Acquir Immune Defic Syndr 2009; 50: 126-36.
19. Stanford University HIV Drug Resistance Database, Stanford University. http://hivdb.stanford.edu/ (8 July 2011, date last accessed).
20. Rhee SY, Fessel WJ, Liu TF et al. Predictive value of HIV-1 genotypic resistance test interpretation algorithms. J Infect Dis 2009; 200: 453-63.
21. Heger E, Thielen A, Gilles R et al. APOBEC3G/F as one possible driving force for co-receptor switch of the human immunodeficiency virus-1. Med Microbiol Immunol 2012; 201: 7-16.
22. Lengauer T, Sander O, Sierra S et al. Bioinformatics prediction of HIV coreceptor usage. Nat Biotechnol 2007; 25: 1407-10.
23. Cardozo T, Kimura T, Philpott S et al. Structural basis for coreceptor selectivity by HIV type 1 V3 loop. AIDS Res Hum Retroviruses 2007; 23: 415-26.
24. Raymond S, Delobel P, Mavigner M et al. Correlation between genotypic predictions based on V3 sequences and phenotypic determination of HIV-1 tropism. AIDS 2008; 22: F11-6.
25. Recordon-Pinson P, Soulié C, Flandre P et al. Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS GenoTropism study. Antimicrob Agents Chemother 2010; 54: 3335-40.
26. Genebat M, Ruiz-Mateos E, León JA et al. Correlation between the Trofile test and virological response to a short-term maraviroc exposure in HIV-infected patients. J Antimicrob Chemother 2009; 64: 845-9.
27. Prosperi MC, Bracciale L, Fabbiani M et al. Comparative determination of HIV-1 co-receptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping. Retrovirology 2010; 7: 56.
28. Poveda E, Alcamí J, Paredes R et al. Genotypic determination of HIV tropism-clinical and methodological recommendations to guide the therapeutic use of CCR5 antagonists. AIDS Rev 2010; 12: 135-48.
29. McGovern RA, Thielen A, Mo T et al. Population-based V3 genotypic tropism assay: a retrospective analysis using screening samples from the A4001029 and MOTIVATE studies. AIDS 2010; 24: 2517-25.
30. Swenson LC, Mo T, Dong WW et al. Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients. J Infect Dis 2011; 203: 237-45.
31. Raymond S, Delobel P, Mavigner M et al. CXCR4-using viruses in plasma and peripheral blood mononuclear cells during primary HIV-1 infection and impact on disease progression. AIDS 2010; 24: 2305-12.
32. Verhofstede C, Brudney D, Reynaerts J et al. Concordance between HIV-1 genotypic coreceptor tropism predictions based on plasma RNA and proviral DNA. HIV Med 2011; 12: 544-52.
33. Noë A, Plum J, Verhofstede C. The latent HIV-1 reservoir in patients undergoing HAART: an archive of pre-HAART drug resistance. J Antimicrob Chemother 2005; 55: 410-2.
34. Turriziani O, Bucci M, Stano A et al. Genotypic resistance of archived and circulating viral strains in the blood of treated HIV-infected individuals. J Acquir Immune Defic Syndr 2007; 44: 518-24.
35. Lehmann C, Däumer M, Boussaad I et al. Stable coreceptor usage of HIV in patients with ongoing treatment failure on HAART. J Clin Virol 2006; 37: 300-4.
36. Perry CM. Maraviroc: a review of its use in the management of CCR5-tropic HIV-1 infection. Drugs 2010; 70: 1189-213.
37. Jensen MA, Li FS, van't Wout AB et al. Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J Virol 2003; 77: 13376-88.
38. Fouchier RA, Brouwer M, Broersen SM et al. Simple determination of human immunodeficiency virus type 1 syncytium-inducing V3 genotype by PCR. J Clin Microbiol 1995; 33: 906-11.
39. Philpott S, Weiser B, Anastos K et al. Preferential suppression of CXCR4-specific strains of HIV-1 by antiviral therapy. J Clin Invest 2001; 107: 431-8.
40. Gulick RM, Lalezari J, Goodrich J et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008; 359: 1429-41.
41. Abbate I, Rozera G, Tommasi C et al. Analysis of co-receptor usage of circulating viral and proviral HIV genome quasispecies by ultra-deep pyrosequencing in patients who are candidates for CCR5 antagonist treatment. Clin Microbiol Infect 2011; 17: 725-31.